Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.13 USD
Change Today +0.26 / 2.63%
Volume 278.9K
TRVN On Other Exchanges
As of 5:20 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

trevena inc (TRVN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/18/15 - $13.57
52 Week Low
12/9/14 - $3.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TREVENA INC (TRVN)

Related News

No related news articles were found.

trevena inc (TRVN) Related Businessweek News

No Related Businessweek News Found

trevena inc (TRVN) Details

Trevena, Inc., a clinical stage biopharmaceutical company, discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors. The company’s central nervous system product pipeline includes TRV130, a small molecule G protein biased ligand at the mu-opioid receptor, which is in Phase II clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-opioid receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain. Its central nervous system product pipeline also comprises TRV250, a small molecule G protein biased ligand of the delta-opioid receptor, which is in preclinical development stage for the treatment-refractory migraine headaches. In addition, the company develops cardiovascular programs, such a TRV027, a peptide beta-arrestin biased ligand that targets the angiotensin II type 1 receptor and is in Phase II clinical trials for the treatment of acute heart failure in combination with standard diuretic therapy. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.

42 Employees
Last Reported Date: 03/18/15
Founded in 2007

trevena inc (TRVN) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $686.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $465.3K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $469.2K
Compensation as of Fiscal Year 2014.

trevena inc (TRVN) Key Developments

Trevena, Inc. Announces Publication of TRV130 Phase 2 Bunionectomy Data

Trevena, Inc. announced the publication of the full results from its Phase 2a/b trial of TRV130 in postoperative pain following bunionectomy surgery. The results successfully demonstrated proof of concept for TRV130, and suggested potential differentiation from morphine. This study provided the company with important insights on the potential differentiation of TRV130 from morphine in a fixed dose setting, paving the way for the positive results from recent Phase 2b trial of the candidate following abdominoplasty surgery. The abdominoplasty study utilized more clinically relevant on-demand dosing and showed better safety and tolerability for TRV130 than morphine with comparable levels of pain relief. TRV130 was designed to optimize opioid receptor pharmacology to deliver an improved analgesic profile. TRV130 is a biased mu-opioid receptor ligand that in preclinical studies activated analgesic signals while avoiding signals that can interfere with analgesia and promote respiratory depression and gastrointestinal dysfunction. In August 2015, Trevena reported data from a Phase 2b trial comparing TRV130 to placebo and morphine following abdominoplasty surgery using on-demand patient-controlled analgesia. In that trial, TRV130 demonstrated comparable efficacy to a standard regimen of morphine, with a significantly lower incidence of nausea, vomiting, and hypoventilation – a measure of respiratory safety. In previous clinical trials, TRV130 delivered profound levels of pain relief safely and rapidly compared to IV morphine, and doses of TRV130 that were more effective than morphine simultaneously depressed respiratory drive to a lesser degree than morphine. Trevena believes that TRV130 may offer an improved safety and tolerability profile compared to currently used opioid analgesics while providing powerful pain relief to patients. Trevena anticipates that the initial market opportunity for TRV130 will be in the acute care settings, with a focus on moderate to severe acute pain in the hospital.

Trevena, Inc. - Special Call

To discuss positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery

Trevena, Inc. Announces Positive Results from Phase 2B Study of TRV130 in Acute Postoperative Pain

Trevena, Inc. announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery. The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours. In addition, TRV130 was superior to morphine in pre-specified secondary measures, exhibiting significantly reduced nausea, vomiting, and hypoventilation events. In the trial, two regimens of TRV130 were tested: the first consisted of a 1.5 mg intravenous loading dose with 0.1 mg self-administered on-demand doses as often as every 6 minutes (together referred to here as “TRV130 0.1 mg”) using a patient controlled analgesia (PCA) device; the second consisted of a 1.5 mg loading dose with 0.35 mg on-demand doses (together referred to here as “TRV130 0.35 mg”) using a PCA device. A commonly used morphine PCA regimen was also tested, consisting of a 4 mg loading dose with 1 mg on-demand doses. Placebo was administered as a loading dose and on-demand doses that were volume-matched to the active regimens. Study Results: Efficacy - TRV130 demonstrated statistically significant pain reduction compared to placebo and comparable efficacy to morphine. The TRV130 0.1 mg regimen reduced average pain scores (LS mean change in time-weighted average over 24 hours) by 2.3 points (p<0.0001 vs. placebo). The TRV130 0.35 mg regimen reduced average pain scores by 2.1 points (p=0.0003 vs. placebo), similar to morphine, which reduced average pain scores by 2.1 points (p=0.0001 vs. placebo). TRV130 provided rapid reduction in average pain scores, consistent with the previous Phase 2 trial where TRV130 showed more rapid onset of meaningful pain relief than morphine. Rescue analgesic use was similar for both TRV130 and morphine, and less than half the rate of rescue analgesic use for placebo. The proportion of patients using rescue analgesic was 64% with placebo, 31% with TRV130 0.1 mg, 21% with TRV130 0.35 mg, and 25% with morphine (post hoc p<0.0005 for all three active arms vs. placebo). Safety and tolerability: In this study, the TRV130 groups had a significantly lower prevalence (percentage of patients) of hypoventilation events (a measure of respiratory safety), nausea, and vomiting than the morphine group (post hoc p<0.05 for both TRV130 regimens vs. morphine). Adverse events associated with TRV130 were largely opioid-related; the most frequently reported events were nausea, vomiting, hypoventilation and headache. Opioid-related AEs were generally less frequent in the TRV130 groups compared to morphine. No drug-related serious adverse events were reported in the study. Total TRV130 use in the study was similar for the two TRV130 regimens with mean cumulative doses of 7.6 mg and 5.4 mg for the TRV130 0.1 mg and TRV130 0.35 mg regimens, respectively. The mean cumulative dose of morphine was 26.3 mg.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRVN:US $10.13 USD +0.26

TRVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRVN.
View Industry Companies

Industry Analysis


Industry Average

Valuation TRVN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TREVENA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at